Tyra Biosciences (TYRA) PT Raised to $37 at Wedbush, Adds to BIL

Wedbush analyst Robert Driscoll raised the price target on Tyra Biosciences (NASDAQ: TYRA) to $37.00 (from $30.00) while maintaining a Outperform rating.

The analyst comments "We are adding TYRA to the Wedbush Best Ideas List ahead of a busy 2026, with data from two ongoing Ph 2 studies in intermediate-grade non-muscle invasive bladder cancer (IR-NMIBC) (1H:26) and in achondroplasia (ACH) (2H:26). TYRA also recently announced plans to initiate a Ph 2 study in upper tract urothelial carcinoma (UTUC) in 2026, which we believe is an underappreciated opportunity and a potential fast-to-market strategy. We are increasing our price target to $37 (from $30) as we realign our model away from the metastatic UC setting to UTUC, and update timelines based on recent guidance."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Stripe, Advent In Talks To Buy Paypal - WSJ
• Critical One Energy closes second tranche of flow-through placement